PD‐L1 expression and FGFR‐mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study

Checkpoint inhibitors have changed the treatment landscape of advanced urothelial carcinoma (mUC), and recently, a fibroblast‐growth‐factor‐receptor (FGFR) inhibitor has been introduced. This study aimed at estimating programmed death‐ligand 1 (PD‐L1) expression in primary tumors (PTs) and the PD‐L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Grantzau, Trine, Toft, Birgitte Grønkær, Melchior, Linea Cecilie, Elversang, Johanna, Stormoen, Dag Rune, Omland, Lise Høj, Pappot, Helle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545015/
https://www.ncbi.nlm.nih.gov/pubmed/35616216
http://dx.doi.org/10.1111/apm.13249

Ejemplares similares

Ejemplares similares